论文部分内容阅读
目的探讨贝那普利(benazepril)对糖尿病大鼠肾脏病变的保护机制。方法采用健康雄性Wister大鼠42只,随机分为正常组、糖尿病组和贝那普利治疗组。实验结束后,取大鼠的尿、血、肾组织标本,行生物化学和聚合酶链反应(polymerasechainreaction,PCR)检测。结果大鼠体质量、肾质量/体质量、血压、血糖,24h尿蛋白定量、血肌酐,尿素氮各组间均有统计学意义(P<0.05);肾组织降钙素基因相关肽(calcitoningene relatedpeptide,CGRP)和内皮素(endothelin,ET)mRNA表达均有统计学意义(P<0.01)。结论贝那普利通过抑制血管紧张素转化酶(angiotensin convertingenzyme,ACE)而减少ET1分泌,促进CGRP合成,从而减轻CGRP与ET1的失衡,对大鼠糖尿病肾脏病变有明确的保护作用。
Objective To investigate the protective mechanism of benazepril on diabetic nephropathy in diabetic rats. Methods Forty-two healthy male Wister rats were randomly divided into normal group, diabetic group and benazepril-treated group. After the experiment, urine, blood and kidney tissue samples of rats were taken for biochemical and polymerase chain reaction (PCR) detection. Results The body weight, kidney mass / body weight, blood pressure, blood glucose, urinary protein excretion in 24h, serum creatinine and urea nitrogen were significantly different among all groups (P <0.05). The calcitonin gene related peptide related peptide, CGRP and endothelin (ET) mRNA expression were significantly (P <0.01). Conclusions Benalipril can reduce ET1 secretion and promote the synthesis of CGRP by inhibiting angiotensin convertingenzyme (ACE), thereby reducing the imbalance of CGRP and ET1 and protecting rat diabetic nephropathy.